TetraPhase raises $45mm in Series C round
Executive Summary
Antibiotics developer TetraPhase Pharmaceuticals Inc. raised $45mm in its Series C financing led by first-time backer Excel Venture Management, which adds a board member. Returning shareholders CMEA Ventures, Fidelity Biosciences, Flagship Ventures, Mediphase Venture Partners, and Skyline Ventures also participated along with eight undisclosed investors. The funds will support ongoing development of its candidates--TP434, a broad-spectrum IV antibiotic set to enter Phase II this year; preclinical TP2758 for complicated urinary tract infections; and preclinical TP834 for community-acquired bacterial pneumonia.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice